Latest Regulatory News

D3 Energy has reported encouraging progress in its South African helium and methane operations, highlighted by improved gas flow rates from the Nooitgedacht Major well and an upgraded US OTCQX listing to broaden investor reach.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Equatorial Resources has completed the final hearing in its high-stakes arbitration against the Republic of Congo and is pursuing clarity on permit cancellations in Guinea, all while maintaining a solid cash reserve.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Critical Resources Limited has secured a $1.75 million placement at market price, reinforcing investor confidence as it advances lithium, gold-antimony, and solid-state battery initiatives.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

Silver Mines Limited has reported its best-ever drilling results at the Bowdens Silver Project in NSW while navigating a complex regulatory redetermination process. Exploration advances continue across its Australian and US projects, supported by a strong cash position.